Introduction
Mounting evidence demonstrated that cell cycle arrests induced by antitumorigenic agents such as retinoic acid, vitamin D 3 , phenylacetate and green tea or cytokines such as TGFb and activin were associated with the induction of various cyclin-dependent kinase inhibitors (CDKIs), including p21 cip , p27 kip , p15 INK4b and p16
INK4a
, accompanied by reduced CDK 4/6 activity and Rb phosphorylation (Zauberman et al. , 1997; Robson et al., 1999; Weber et al., 1999; Onishi et al., 2000; Verlinden et al., 2000; Kavanagh et al., 2001) . Of the CDKIs, p15
INK4b and p16 INK4a genes were suggested to be tumor suppressive genes (Serrano et al., 1996; Latres et al., 2000) , which were inactivated either by deletion of the gene or methylation on the promoter in many tumors including hepatocellular carcinoma (Roussel, 1999; Jin et al., 2000) . Overexpressions of both genes result in growth arrest in several in vitro and in vivo systems (Campbell et al., 2000; Fuxe et al., 2000) . We have reported the induction of p15
INK4b and p16 INK4a (but not p21 cip and p27 kip ) together with decreased Rb phosphorylation during hepatoma cell HepG2 growth inhibition triggered by antitumorigenic Chinese herb Saikosaponin a and the tumor promoter TPA (Wu and Heu, 2001 ); however, the mechanisms for p15 INK4b INK4a are located very closely on the same chromosome, the transcriptional activation systems responsible for their inductions seem not to be the same. Joan et al reported that induction of p15
INK4b during TGFb-triggered growth inhibition was associated with downregulation of myc by Miz (Seoane et al., 2001) , whereas a recent report demonstrated that p16
INK4a expression was regulated by one of the jun family proteins, junB (Passegue and Wagner, 2000) . It is worth noting that myc is a positive regulator of cell growth (Faacchini and Penn, 1998) whereas junB is the negative regulator of cell cycle counteracting the function of c-jun (Fatima et al., 2001) . Intriguingly, inductions of both p15
INK4b and p16 INK4a promoters were also shown to be mediated in cultured cells by the RAS/ Raf/MEK/MAPK(ERK) pathway (Malumbers et al., 2000) . The MAPK family, including ERK, JNK and p38 have proved to mediate cell proliferation, stress response and growth inhibitory effects induced by a variety of agonists in several cultured systems. For example, ERK activation is responsible for TPA, gonadotropin-releasing hormone and oncostatin-induced G0/G1 arrest of breast cancer cells, ovarian cell line and glioma cell, respectively (Agadir et al., 1999; Halfter et al., 1999; Kimura et al., 1999) and p38 activation is required for growth inhibition of breast cancer induced by activin (Cocolakis et al., 2001) . Furthermore, the MAPK cascades mediate a number of cellular effects through regulation of a variety of transcriptional factors such as ATF2, ELK, c-jun, c-fos and AP-1 activity (Franklin and Kraft, 1995; Gille et al., 1995; Hochholdinger et al., 1999; Yang et al., 1999) some of which were also known to be activated by TPA (Fatima et al., 2001; Dam and Castellazzi, 2001) . Taken together, it is tempting to investigate whether and which of the MAPK signaling pathways along with their downstream transactivating systems mediate p15
INK4b and p16
INK4a induction leading to growth inhibition of HepG2 by TPA and Saikosaponin a.
Results

Phosphorylation of ERK and JNK but not p-38 is induced during TPA-and Saikosaponin a-triggered HepG2 growth inhibition
To investigate whether MAPK cascades are induced by TPA and Saikosaponin a, we performed Western blot of activated forms of the three MAPKs, that is, phosphorylated ERK (p-ERK), phosphorylated JNK (p-JNK) and phosphorylated p-38 (p-p38) in cell extracts of HepG2 treated with both drugs. Figure 1 (upper panel) demonstrated that phosphorylated ERK is dramatically increased (11.6-fold) after TPA (50 nm) treatment for 15 min and sustained until 1 h, whereas much less but significant induction (by 2.5-fold) of ERK phosphorylation by Saikosaponin a (12.5 mg/ml) was also observed at 30 min and declined to basal level at 60 min. On the other hand, phosphorylation of JNK was induced only by TPA at 30 min (1.4-fold) and 1 h (2.5-fold), but not induced by Saikosaponin a (Figure 1 , middle panel). Western blot of ERK and JNK indicated that the amounts of ERK and JNK proteins in each sample were equal. An increase of phosphorylated p-38 was not observed in cells treated by both drugs (Figure 1 , lower panel).
Phosphorylation of ATF2 and c-jun induced by TPA and Saikosaponin a in HepG2 cell
Since several important nuclear transcriptional factors such as ATF2, ELK-1 and c-jun were reported to be downstream effectors of JNK and ERK (for a review, see Waskiewicz and Cooper, 1995) , it is very probable that they are activated in TPA-and Saikosaponin atreated HepG2 cells. Western blot of p-ATF2 demonstrated that phosphorylation of ATF2 was maximally induced by TPA at 15 min (by 3.2-fold) and Saikosaponin a at 30 min (by 2.0-fold), followed by gradual declination until 1 h (Figure 2 , upper panel). Phosphorylation of the other transcriptional factor, c-jun, was significantly induced by TPA during 30 min to 1 h, but not induced by Saikosaponin a. (Figure 2 , middle panel). Elk-1 phosphorylation was not induced by both drugs (Figure 2 , lower panel).
Inductions of immediately early responsive genes by TPA and Saikosaponin a
Immediately early responsive genes such as c-fos and the Jun family proteins, c-jun, junB and junD, have been well known to be activated through MAPK cascades in response to many stimulators including TPA (Waskiewicz and Cooper, 1995; Wang and Prywes, 2000; Fatima et al., 2001) . We thus analyse whether they are induced in TPA-and Saikosaponin a-treated Figure 1 Western blot of p-ERK, p-JNK and p-p38 in TPA-and Saikosaponin a-treated HepG2 cells. Cell lysates of HepG2 treated with TPA for 15, 30 and 60 min or Saikosaponin a for 30 and 60 min were electrophoresed in 12% SDS-PAGE followed by Western blot of p-ERK, p-JNK and p-p38, respectively, as described in experimental procedures. Western blottings of ERK and JNK were performed for normalizing the amount of protein in each sample Figure 2 Western blot of phosphorylated p-ATF2, p-c-jun and p-ELK in TPA-and Saikosaponin a-treated HepG2 cells. Cell lysates of HepG2 treated with TPA or Saikosaponin a for 0, 15, 30 and 60 min were electrophoresed in 12% SDS-PAGE followed by Western blot of p-ATF2, p-c-jun and p-ELK as described in experimental procedures HepG2 cells. Semiquantitations for gene expressions of the treated and untreated HepG2 cells were performed by RT/PCR and normalized by the coamplified GAPDH as an internal control. As demonstrated in Figure 3 , c-jun was not only dramatically induced (10-fold) by TPA but also by Saikosaponin a (eight-fold) after 30 min and sustained until 8 h (upper panel). The basal level of junB is higher than c-jun in untreated HepG2 cells and significant induction of junB was observed in TPA-treated HepG2 cells during 30 min to 6 h with a maximum at 2 h (3.5-fold). Less induction of junB was observed in Saikosaponin a-treated cells during the same period (middle panel). junD was slightly induced by TPA but not by Saikosaponin a (data not shown). Biphasic induction of c-fos was observed in TPA-treated cells with the maximum at 30 min and 4 h (8.5-and 10-fold increase, respectively) while 3.5-fold induction of c-fos was observed at 2 h in Saikosaponin a-treated cells ( Figure 3 , lower panel).
Prevention of TPA-and Saikosaponin a-triggered HepG2 growth inhibition by PD98059
According to the results shown above, it seems that activation of the two MAPKs, that is, ERK and/or JNK, along with their downstream transactivating systems might mediate growth inhibition of HepG2 induced by TPA and Saikosaponin a. To address the issue, we used inhibitors of the two MAPKs -one is PD98059 for ERK, and the other is dicumarol for JNKto examine whether the growth inhibitory effect is prevented. As demonstrated in Figure 4 , after 50 nm TPA and 12.5 mg/ml Saikosaponin a treatment for 48 h, 65 and 50% of HepG2 cell growth were inhibited respectively. When HepG2 cells were pretreated with PD98059 (20 mg/ml) for 2 h followed by TPA or Saikosaponin a treatment for 48 h, the suppression of growth decreased from 65 to 15% in TPA-and from 50 to 30% in Saikosaponin a-treated cells. HepG2 cell growth was not influenced by PD98059 treatment only. In addition, Western blot of p-ERK proved that in cells pretreated with PD98059 for 2 h the phosphorylations of ERK induced by TPA (at 15 and 30 min) and Saikosaponin a (at 30 min) were indeed abolished (Figure 5a) . Interestingly, the prevention of growth inhibition by PD98059 is more efficient in TPA (50% prevention)-than Saikosaponin a (20% prevention)-treated cells. This is in accordance with the much more ERK activity reduced by PD98059 pretreatment in TPA-than Saikosaponin a-treated cells (compare Figures 4 and 5a) . On the other hand, pretreatment of the JNK inhibitor dicumarol (100 mg/ml) did not prevent any growth inhibitory effect (Figure 4) . These results suggest that the growth inhibitory effect of TPA and Saikosaponin a (to a less extent) on HepG2 is mediated by the ERK pathway. (Figure 6a ). Western blot analysis (Figure 7 ) also demonstrated that TPA induced a 6.0-fold increase of p15
INK4b protein and a 2.5-fold increase of p16
INK4a protein, which were 85 and 50% suppressed by PD98059, respectively. In the same experiments, Saikosaponin a induced a 2.5-fold increase of p15
INK4b protein and a 3.0-fold increase of p16
INK4a protein, which were 80 and 55% suppressed by PD98059, respectively. Western blot of ERK demonstrated an equal amount of protein in each sample. These results strongly suggest that inductions of both INK4 genes by TPA and Saikosaponin a were mediated by the ERK pathway. On the other hand, inductions of the immediate early gene c-fos by TPA and Saikosaponin a at 2 h were also 60% reduced by 2 h PD98059 pretreament ( Figure 6b ) whereas inductions of c-jun and junB (at 30 min and 2 h time point) were not ( Figure 6c , data not shown). In the post-translational level, the TPA-induced c-jun phosphorylation was also 50 and 30% reduced by 2 h PD98059 pretreatment at 15 and 30 min, respectively (Figure 5b ).
Induction of AP1 activity by TPA and Saikosaponin a
The AP-1 complex is an important transcriptional factor that can be activated by a number of agonists, including TPA, to mediate various cellular effects such as cell proliferation, terminal differentiation, apoptosis and growth arrest (Shaulian and Karian, 2001 ). Thus, we INK4a in HepG2 cells treated with TPA or Saikosaponin a for 24 h, or in cells pretreated with PD98059 (20 mm) for 2 h followed by TPA or Saikosaponin a treatment for 24 h. Western blot of ERK was performed to normalize the amount of protein in each sample ERK activation mediates HepG2 growth inhibition W Wen-Sheng AP-1 DNA probe increased by 100, 93 and 67%, respectively, as compared with that of control cells (Table 1) . No significant change of complex IV was observed. Pretreatment (for 2 h) of PD98059 attenuated the TPA-induced elevations of the peak area ratios of these complexes to the AP-1 DNA probe (Figure 8d and Table 1 ). On the other hand, all the four complexes increased in AP-1 assay mixture for cells treated with Saikosaponin a for 30 min (Figure 8e) . The peak area ratio of complexes I, II, III and IV to the AP-1 DNA probe increased by 237, 278, 328 and 38.9%, respectively, as compared with that of control cells (Table 1 ). The increases of these complexes induced by Saikosaponin a were also attenuated by PD98059 pretreatment (Figure 8f and Table 1 ). To our surprise, all the AP-1-related DNA-binding complexes (especially complex III) were induced by Saikosaponin a much more than by TPA, and can be efficiently suppressed by PD98059 pretreatment. Further characterization of all the AP-1-related complexes must be performed to identify which complex(es) is (are) relevant to TPA-and Saikosaponin a-induced AP-1 activity responsible for growth inhibition.
Discussion
In this study we suggest that the MAPK (ERK) pathway is associated with HepG2 growth inhibition induced by TPA and Saikosaponin a. Initially, ERK was regarded as a mitogen-activated protein kinase mediating cell proliferation. However, a great deal of further evidence demonstrated that sustained ERK activity is associated with cell cycle arrest (Hartsough et al., 1996; Pumiglia and Decker, 1997; Serrano et al., 1997; Woods et al., 1997; Bosch et al., 1998; Lin et al., 1998; Lioyd, 1998; Roovers and Assoian, 2000) . Most of the studies indicated that the Ras/Raf/ERK pathway mediated CDKI expressions (such as p21 cip and p27 kip ), which are responsible for cell cycle arrest. For example, the antiproliferative effect mediated by Raf signaling requires p21 cip induction (Serrano et al., 1997) . Our results demonstrated that inductions of p15
INK4b and p16
INK4a , on both RNA and protein levels, were mediated by the ERK signaling pathway (Figures 6a  and 7 ). These two INK4 family genes were important regulators of the cell cycle, and the induction of both genes might be responsible for HepG2 growth arrest induced by TPA and Saikosaponin a. This is in agreement with several recent reports demonstrating that both p15 INK4b and p16 INK4a promoters are activated by the Ras/Raf/ERK pathway to mediate cell cycle arrest (Malumbers et al., 2000) , and that premature senescence involved p16
INK4a activation in response to constitutive MEK/MAPK signaling (Lin et al., 1998) .
It seems that the ERK pathway mediated HepG2 growth arrest induced by Saikosaponin a to a less extent than by TPA. Firstly, phosphorylation of ERK by Saikosaponin a (2.5-fold) was much less than that by TPA (11-fold) (Figure 1) . Secondly, the efficiency of PD98059 for preventing HepG2 growth arrest induced by Saikosaponin a was less than that induced by TPA (Figure 4) . However, we unexpectedly found that AP-1-related DNA-binding activity was greatly induced by Saikosaponin a and can be efficiently prevented by PD98059 (Figure 7) . The role of ERK and AP-1 activation in Saikosaponin a-induced HepG2 growth inhibition and whether other signaling pathways are also involved need further investigation.
In addition to ERK, we also found that phosphorylation of JNK (Figure 1 ) was induced by TPA only. This seems to be correlated with the experiment that c-jun phosphorylation was induced by TPA only (Figure 2) . Since c-jun is the major target of JNK (Waskiewicz and The peak area of each complex was calculated by 3-D ChemStation software (Agilent Tech. 1990 -2000 . b X is denoted as I, II, III or IV. c HepG2 cells were without any treatment (control) or treated with TPA (TPA), Saikosponin a (Saiko) for 30 min or pretreated with PD 98059 for 2 h followed by TPA (TPA/PD) or Saikosaponin a (Saiko/ PD) for 30 min Cooper, 1995) , it is possible that TPA-induced c-jun phosphorylation was mediated by JNK. However, we found that TPA-induced c-jun phosphorylation can be partially prevented by PD98059, indicating that the ERK pathway is also involved (Figure 5b ). In addition, the JNK-mediated pathway was not involved in TPAinduced HepG2 growth inhibition because dicumarol, the JNK inhibitor, did not prevent this effect (Figure 4) . It can be speculated that ERK-mediated c-jun phosphorylation plays some role in TPA-triggered HepG2 growth inhibition.
How ERK activation leads to induction of both INK4 family genes needs further investigation. After its activation, ERK enters the nucleus to phosphorylate transcriptional factors such as ELK-1, ATF2 and c-jun and induce expressions of immediate early responsive genes c-jun, junB and c-fos resulting in AP-1 activation (Waskiewicz and Cooper, 1995) . The AP-1 complexes are homodimers or heterodimers composed of proteins that belong to the Jun, Fos and ATF families depending on what cellular effect it mediates. The activation of AP-1 occurs through regulations of these transcriptional factors at both transcriptional and post-translational levels (Karin, 1995; Karin et al., 1997) . We have demonstrated phosphorylation of ATF2 induced by both TPA and Saikosaponin a and also phosphorylation of c-jun induced by TPA (Figure 2 ). On the other hand, we have observed that gene expressions of c-fos, c-jun and junB were induced by TPA and Saikosaponin a (Figure 3 ). In addition, the induction of c-fos and phosphorylation of c-jun were significantly prevented by PD98059 pretreatment (Figure 6b ). Taken together, regulations of these transcriptional factors at both transcriptional and post-translational levels might be involved in TPA-and Saikosaponin a-induced AP-1-related binding activities. Further studies such as AP-1 DNA mobility shift assay coupled with antibody-directed supershift analysis should be carried out to identify which transcriptional factors are involved in AP-1 activation induced by both the drugs.
Whether the TPA-and Saikosaponin a-induced p15
INK4b and p16 INK4a gene expressions were transactivated by AP-1 is not quite established. Emmanuelle et al. reported that p16 INK4a expression was regulated by one of the jun family proteins, junB, and that the promoter region of p16
INK4a contains an AP-1 binding site mediating its induction by junB (Passegue and Wagner, 2000) , whereas Joan et al. reported that the promoter region of p15
INK4b contains an Sp1 binding site and an Inr (transcriptional initiator) element that is responsive for TGFb induction (Seoane et al., 2001) . Further characterization of the promoter regions involved in p15
INK4b and p16 INK4a induction by both drugs might clarify this issue.
One of the mechanisms of uncontrolled cellular proliferation of cancer is escape of the cancer cell from normal growth regulatory machinery (Gold, 1999; Derynck et al., 2001) . Our system might be used as a model for studying the detailed mechanisms of growth inhibitions and be of benefit for developing chemotherapy and gene therapy for cancer. To confirm the results shown above, further studies using gene transfer techniques to investigate how activation of ERK and downstream transactivating machinery trigger p15
INK4b and p16
INK4a induction and HepG2 growth inhibition are needed.
Materials and methods
Cell line and growth inhibition study 
RT/PCR analysis
HepG2 cells were seeded in a 10-cm dish for 48 h and treated with Saikosaponin a, TPA and/or PD98059 as indicated. Total RNAs were purified with Ultraspec RNA reagent (Biotecx). First stranded cDNAs were synthesized by AMV transcriptase with oligo-dT primer (GIBCO) using 1 mg RNA of each sample. Semiquantitation of the cDNA was performed by RT/ PCR using the primer-dropping method according to a previous report (Wong et al., 1994) . Each reverse transcript (i.e. p15
INK4b
, p16 ink4a , c-jun, c-fos, junB cDNA) was coamplified with GAPDH as an internal control. The primers of the internal control were added at a later PCR cycle to minimize the competition effect for Taq polymerase and the PCR substrate because of a large amount of GAPDH transcript. Under standard conditions of PCR, all the test transcripts were amplified within their log linear phase after 35 PCR cycles (data not shown). The GAPDH primers were dropped at cycle 17 for p15 INK4b , p16
INK4a
, and cycle 12 for c-jun, c-fos and junB. The primers used were:
PCR condition After initial denaturation at 951C for 5 min, amplification was achieved with 3% formamide (for p15   INK4b   and p16   ink4a ) or without formamide (for c-fos, c-fos, c-jun, junB and junD) by 35 cycles of denaturation at 941C for 40 s, annealing at 531C for 1 min and extension at 721C for 40 s.
Quantitative analysis For comparing the amount of PCR product between samples, a gel digitizing software, UN-SCAN-IT gel (version 5.1), was used for estimating the intensity of each band on the gel. Each experiment was repeated two-four times. The coefficients of variation (cV) were about 4-8%.
Immunoblotting
The cells were lyzed in buffer containing 50 mm Tris at pH 7.4, 50 mm NaCl, 1% Triton X-100, 0.1% SDS, 0.3 mm Naorthovanadate, 50 mm NaF, 1 mm DDT, 10 mg/ml leupeptin and 5 mg/ml aprotinin. Protein concentrations were determined by BCA reagent (Pierce). An equal amount of protein in each sample was separated by 12% SDS/PAGE and transferred to nitrocellulose membrane. Membranes were blocked in 20 mm Tris (pH 7.6), 250 mm NaCl containing 5% dry milk and probed with mouse anti-p-ERK-1 anti-p-JNK-1, anti-p-p38, anti-pATF2, anti-p-c-jun monoclonal antibody or anti-ERK, anti-JNK, anti-p38, anti-c-jun, anti-ATF2 polyclonal antibody or anti-p16
INK4a (Santa Cruz) and anti-p15 INK4b (Oncogene) monoclonal antibody. Following incubation with peroxidaseor alkaline phosphatase-conjugated goat anti-mouse, or goat anti-rabbit 2nd antibody, proteins were visualized with lumigo chemiluminence detection system or NBT/BCIP color development. For quantitation, the blots were scanned and the intensity of each specific band was estimated with gel digitizing software UN-SCAN-IT gel version 5.1. Each experiment was repeated two-five times. The cV were about 6.0-10.5%.
AP-1 DNA-binding assay
Labeled AP-1 was synthesized as described previously (Foulds and Etzkorn, 1998) . d(5 0 -AAACTGAGTCATAGGA-3 0 ) (3 nm) and Xd(5 0 -TTCCTATGACTCATCCAGTT-3 0 ), (2 nm) where X is flurescent FAM, were freshly annealed at 901C for 5 min and cooled slowly to room temperature. For nuclear extract preparation, the trypsinized cells were suspended in hypotonic buffer (20 mm Tris, 50 mm EDTA, 10 mg/ml leupeptin and 5 mg/ml aprotinin) for swelling. After repeated freezing (À701C) and thawing, the cell homogenates were centrifuged at 2500 g for 10 min to remove supernatant. The pellets were then incubated in lysis buffer (50 mm Tris, 50 mm EDTA, 1% Triton X, 10 mg/ml leupeptin and 5 mg/ml aprotinin) for 1 h followed by centrifugation at 12000 g for 15 min to obtain nuclear extract. A measure of 10 mg of each nuclear extract was used for AP-1 binding assay with the FAM labeled AP-1 DNA fragment as described previously (Foulds and Etzkorn, 1998) . Capillary electrophoresis (CE) was performed on an Agilent CE system with a laser induced fluorescence (excited at 514 nm) detection system (Picometric) in 75 mm ID, 60-cm-long uncoated capillaries with the condition of CE as described (Foulds and Etzkorn, 1998) . Before runs, the capillaries were rinsed with run buffer (10 mm MOPS-Et 3 N, pH 7.5) for 3 min. Samples were injected for 10 s at low pressure and electrophoresed at 25 kV at normal CE polarity (cathode at detector end).
